NCT00096798

Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression

A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: National Center for Complementary and Integrative Health (NCCIH) · NIH
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.

Detailed description

Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. This study will determine whether ethyl-EPA, an omega-3 fatty acid, can be used safely and effectively to treat major depression. Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks. Each week, participants will be asked to complete questionnaires which will be used to assess the severity of their depression.

Conditions

• Depressive Disorder
• Depression

Interventions

Type	Name	Description
DRUG	Ethyl-eicosapentanoic acid (ethyl-EPA)

Timeline

• Start date: 2001-09-01
• Primary completion: 2007-08-01
• Completion: 2007-08-01
• First posted: 2004-11-16
• Last updated: 2008-01-17

Locations

1 site across 1 country: United States